Cell>Point LLC   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Centennial CO United States (2001)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2009
NCT00865319
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

99mtc ecdg (4 trials)

fludeoxyglucose f-18 (3 trials)

Drugs in Phase 2 Trials (1)

technetium tc-99m sestamibi (Cardiolite) (1 trial)

Drugs in Phase 1 Trials (1)

99mtc ethylenedicysteine-deoxyglucose (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Coronary Artery Disease (Phase 2)

Coronary Disease (Phase 2)

Lung Neoplasms (Phase 3)

Myocardial Ischemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4